Temozolomideacid

Temozolomideacid Property

Melting point:

166-168°C

Boiling point:

487.7±37.0 °C(Predicted)

Density 

1.97±0.1 g/cm3(Predicted)

storage temp. 

Inert atmosphere,2-8°C

solubility 

DMSO (Slightly), Methanol (Slightly)

pka

2.88±0.20(Predicted)

form 

Solid

color 

White to Off-White

Stability:

Hygroscopic

Safety

HS Code 

2933.99.9000

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H302Harmful if swallowed

H340May cause genetic defects

H350May cause cancer

H360May damage fertility or the unborn child

H372Causes damage to organs through prolonged or repeated exposure

Precautionary statements

P260Do not breathe dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P314Get medical advice/attention if you feel unwell.

P330Rinse mouth.

P501Dispose of contents/container to..…

Temozolomideacid Chemical Properties,Usage,Production

Chemical Properties

White Solid

Uses

A metabolite of Temozolomide (T017775) as antitumor agent.

Synthesis

General procedure: Example 1 Preparation of 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid (EP0252682) 1. 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide (2.577 mmol, 0.5 g) was mixed with concentrated sulfuric acid (4 mL) under stirring conditions. 2. a solution was prepared by dissolving sodium nitrite (9.4 mmol, 0.65 g) in 2.6 mL of water. 3. Slowly add the aqueous sodium nitrite solution dropwise to the above mixture under cooling in an ice bath (keeping the temperature below 15°C). 4. After the dropwise addition, the reaction mixture was stirred at room temperature overnight. 5. 10 g of ice was added to the reaction mixture and cooling was continued in an ice bath for 1 hour. 6. The solid product was collected by filtration. 7. The collected solid product was dried under vacuum to give 0.493 g of 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid. The yield was 98.6%.

References

[1] European Journal of Medicinal Chemistry, 2002, vol. 37, # 4, p. 323 - 332
[2] Patent: EP1798234, 2007, A1. Location in patent: Page/Page column 11
[3] Patent: US2018/79754, 2018, A1. Location in patent: Paragraph 0082; 0101-0102
[4] European Journal of Medicinal Chemistry, 2017, vol. 127, p. 691 - 702
[5] Journal of Medicinal Chemistry, 2002, vol. 45, # 25, p. 5458 - 5470